Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas

European Journal of Haematology

Volumn 71, Issue 2, 2003, Pages 91-99

  Kuittinen, Outi ^a   Apaja Sarkkinen, Meeri ^a   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Collagenase; Factor VIII; Invasion; Matrix metalloproteinase; Non Hodgkin's lymphoma; Prognosis; Prognostic factors; TIMP 1

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 7; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEOVASCULARIZATION (PATHOLOGY); NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; STAINING; SURVIVAL TIME; TUMOR VASCULARIZATION;

BIOLOGICAL MARKERS; COLLAGENASES; DISEASE PROGRESSION; FACTOR VIII; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0041627545     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00101.x     Document Type: Article

References (32)

1. World Health Organization classification of tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC press, 2001.
2. OOSTEROM AT, JUDSON I, VERWEU J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
3. BIRKEDAL-HANSEN H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-735.
4. ECCLES SA, BOX GM, COURT WJ, BONE EA, THOMAS W, BROWN PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB-94). Cancer Res 1996;56:2815-2822.
5. VÄISÄNEN A, TUOMINEN H, KALLIOINEN M, TURPEENNIEMI-HUJANEN T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996;180:283-289.
6. VACCA A, RIBATTI D, PRESTA M, MINISCHETTI M, IURLARO M, RIA R. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;9:3064-3073.
7. VÄISÄNEN A, KALLIOINEN M, TASKINEN PJ, TURPEENNIEMI-HUJANEN T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998;86:51-58.
8. TALVENSAARIA-MATILLA A, PÄÄKKÖ P, HÖYHTYÄ M, BLANCO-SEQUEIROS G? TURPEENNIEMI-HUJANEN T. Matrix Metalloproteinase-2 Immunoreactive Protein a Marker of Aggressiveness in Breast Carcinoma. Cancer 1998;83:1153-1162.
9. GOETZL EJ, BANDA MJ, LEPPERT, D. Matrix metalloproteinases in immunology. J Immunol 1996;156:1-4.
10. FASSINA G, FERRARI N, BRIGATI C, BENELLI R, SANTI L, NOONAN DM, ALBINI A. Tissue inhibitors of metalloproteinases: regulation and biological activities. Clin Exp Metas 2000;18:111-120.
11. ITOH T, IKEDA T, GOMI H, NAKAO S, SUZUKI T, ITOHARA S. Reduced angiogenesis and tumour progression in gelatinase-A deficient mice. J Biol Chem 1997;272:22389-22392.
12. VACCA A, MORETTI S, RIBATTI D, PELLEGRINO A, PIMPINELL N, BIANCHI B, BONIFAZI E, RIA R, SERIO G, DAMMACCO F. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 1997;33:1685-1692.
13. VACCA A, RIBATTI D, RUCO L, GIACCHETTA F, NICO B, QUONDAMATTEO F, RIA R, IURLARO M, DAMMACO F. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer, 1999;79:965-970.
14. HSU SM, RAINE L, FANGER H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem and Cytochem 1981;29:557-580.
15. KOSSAKOWSKA AE, URBANSKI SJ, WATSON A, HAYDEN LJ, EDWARDS DR. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 1993;5:19-28.
16. KOSSAKOWSKA AE, URBANSKI SJ, HUCHCROFT SA, EDWARDS DR. Relationship between clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinase (TIMP-1) RNAs. Oncol Res 1992;4:233-240.
17. KOSSAKOWSKA AE, HINEK A, EDWARDS DR, LIM MS, ZHANG CL, BREITMAN DR, PRUSINNKIEWICZ C, STABBLER AL, URBANSKI LS, URBANSKI SJ. Proteolytic activity of human on-Hodgkin's lymphomas. Am J Pathol 1998;152:565-576.
18. AOUDJIT F, POTWOROWSKI EF, ST-PIERRE Y. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metallorpoteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. J Immunol 1998;160:2967-2973.
19. LALANCETTE M, AOUDJIT F, POTWOROWSKI EF, ST-PIERRE Y. Resistance of ICAM-1 deficient mice to metastasis overcome by increases aggressiveness of lymphoma cells. Blood 2000;95:314-319.
20. AOUDJIT F, MASURE S, OPDENAKKER G, POTWOROWSKI EF, ST-PIERRE Y. GELATINASE B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int J Cancer 1999;82:743-747.
21. KOSSAKOWSKA AE, EDWARDS DR, PRUSINKIEWICZ C, ZHANG MC, GUO D, URBANSKI SJ, GROGAN T, MARQUEZ LA, JANOWSKA-WIECZOREC A. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999;94:2080-2089.
22. SHEU BC, Hsu SM, HO H, LIEN HC, HUANG SC, LIN RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61:237-242.
23. YLISIRNIÖ S, HÖYHTYÄ M, MÄKITARO R, PÄÄKKÖ P, RISTELI J, KINNULA VL, TURPEENNIEMI-HUJANEN T, JUKKOLA A. Elevated levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001;7:1633-1637.
24. GUEDEZ L, COURTEMANCH L, STETLER-STEVENSON M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998;92:1342-1439.
25. GUEDEZ L, STETLER-STEVENSON WG, WOLFF L, WANG J, FUKUSHIMA P, MANSOOR A, STETLER-STEVENSON M. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998;102:2002-2010.
26. GUEDEZ L, MCMARLIN AJ, KINGMA DW, BENNETT TA, STETLER-STEVENSON M, STETLER-STEVENSON WG. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumour growth and angiogenesis. Am J Pathol 2001;158:1207-1215.
27. YLISIRNIÖ S, HÖYHTYÄ M, TURPEENNIEMI-HUJANEN T. Serum matrix metalloproteinases-2, and -9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res 2000;20:1311-1316.
28. KRUGER A, FATA JE, KHOKHA R. Altered tumour growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 1997;90:1993-2000.
29. BERGERS G, BREKKEN R, MCMAHON G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744.
30. DAVIS GE, PINTAR AKA, SALAZAR R, MAXWELL SA. Matrix metalloproteinase-1 and-9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 2001;114:917-930.
31. KUITTINEN O, SAVOLAINEN EV, KOISTINEN P, TURPEENNIEMI-HUJANEN T. Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res 1999;19:4395-4400.
32. BUTLER GS, BUTLER MJ, ATKINSON SJ, WILL H, TAMURA T, VAN WESTRUM SS, GARBBE T, CLEMENTS J, DÓRTHO MP, MURPHY G. The TIMP-2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998;273:871-880.